Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib with Concurrent Chemoradiotherapy for Limited-stage SCLC
NCT04882033Phase 1Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anlotinib in small cell lung cancer (SCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Maximum Tolerance Dose at 18 months. Status: unknown.
02
Drugs
anlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04882033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04882033.